3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 1
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
157
Nivolumab
132
Ipilimumab
77
Cyclophosphamide
46
Specimen Handling
44
Magnetic Resonance Spectroscopy
39
cemiplimab
35
Biopsy
31
fludarabine
28
trametinib
24
relatlimab
24
binimetinib
23
Interleukin-2
21
fludarabine phosphate
20
dabrafenib
20
atezolizumab
20
Radiotherapy
20
Opdualag
19
Radiosurgery
18
CTLA-4 Antigen
18
encorafenib
17
aldesleukin
17
Blood Specimen Collection
17
avelumab
14
Immunoglobulin G
14
Disulfides
13
lenvatinib
11
Bevacizumab
11
lifileucel
10
Paclitaxel
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
High-Intensity Focused Ultrasound Ablation
×
Dermatologic
×
1 year
×
Clear all
NCT06472661
2025-11-20
Mel 70
University of Virginia
Phase EARLY_PHASE1
Recruiting
11 enrolled
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled